soul trial oral semaglutide cardiovascular outcomes 2025 Projected reduction in major adverse events among high-risk U.S. adults with type 2 diabetes eligible for semaglutide: a trial–based analysis using NHANES (1988–2018) cycles NEJM Editorial Fellow Harleen Marwah,
Pay in 4 interest-free payments of $7.19 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7



























